66.29
0.11%
+0.13
Overview
News
Price History
Option Chain
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences, Inc. stock is currently priced at $66.29, with a 24-hour trading volume of 3.70M.
It has seen a +0.11% increased in the last 24 hours and a -9.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $66.36 pivot point. If it approaches the $65.70 support level, significant changes may occur.
Gilead Sciences, Inc. Stock (GILD) Financials Data
Gilead Sciences, Inc. (GILD) Revenue 2024
GILD reported a revenue (TTM) of $27.11 billion for the quarter ending December 31, 2023, a -0.61% decline year-over-year.
Gilead Sciences, Inc. (GILD) Net Income 2024
GILD net income (TTM) was $5.66 billion for the quarter ending December 31, 2023, a +23.34% increase year-over-year.
Gilead Sciences, Inc. (GILD) Cash Flow 2024
GILD recorded a free cash flow (TTM) of $7.42 billion for the quarter ending December 31, 2023, a -11.06% decrease year-over-year.
Gilead Sciences, Inc. (GILD) Earnings per Share 2024
GILD earnings per share (TTM) was $4.50 for the quarter ending December 31, 2023, a +23.29% growth year-over-year.
Gilead Sciences, Inc. Stock (GILD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Parsey Merdad | Chief Medical Officer |
Apr 01 '24 |
Sale |
72.96 |
2,000 |
145,920 |
96,304 |
Parsey Merdad | Chief Medical Officer |
Feb 29 '24 |
Sale |
72.74 |
8,230 |
598,624 |
92,706 |
Parsey Merdad | Chief Medical Officer |
Feb 28 '24 |
Sale |
73.18 |
2,000 |
146,360 |
100,936 |
GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
GILEAD SCIENCES, INC. | 10% Owner |
Jan 29 '24 |
Buy |
21.00 |
15,238,095 |
319,999,995 |
30,061,124 |
Dickinson Andrew D | Chief Financial Officer |
Jan 16 '24 |
Sale |
85.78 |
5,000 |
428,900 |
101,534 |
Mercier Johanna | Chief Commercial Officer |
Jan 09 '24 |
Sale |
85.23 |
8,242 |
702,466 |
82,729 |
Dickinson Andrew D | Chief Financial Officer |
Oct 17 '23 |
Sale |
80.00 |
5,000 |
400,017 |
104,003 |
Parsey Merdad | Chief Medical Officer |
Sep 12 '23 |
Sale |
76.99 |
1,501 |
115,562 |
70,130 |
Dickinson Andrew D | Chief Financial Officer |
Jul 20 '23 |
Sale |
80.00 |
5,000 |
400,000 |
107,587 |
Gilead Sciences, Inc. Stock (GILD) Latest News
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks Investment Research
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Pfizer's Doldrums, Just A Bad Case Of COVID-19?
Seeking Alpha
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks Investment Research
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
Better Growth Play: Merck or The Vanguard Growth Index Fund?
The Motley Fool
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Cap:
|
Volume (24h):